Oct 21, 2026
We give CVS Health a narrow economic moat rating with a stable trend and medium uncertainty. The company's competitive edge comes from switching costs in pharmacy benefit management and insurance, along with a cost advantage from vertical integration. Fluctuating medical costs keep us from awarding a wider rating.
Recent financial results support parts of this view. CVS raised its full-year 2026 adjusted EPS guidance to $7.90–$8.10, up from an earlier range of $7.30–$7.50, following strong Q2 2026 results. According to the same earnings release, Aetna's medical benefit ratio improved to 87.4% from 89.9% a year earlier.
Here are our primary conclusions:
Competitive durability determines whether CVS can compound value over a full decade. Below, we examine each moat pillar, assess how these advantages appear in the numbers, and outline what might change our rating.
Scale and switching costs sustain CVS's competitive moat. We assess each pillar below from strongest to weakest based on whether it generates returns above the cost of capital over time.
CVS's massive footprint across retail pharmacies, PBM operations, insurance plans, and walk-in clinics gives it meaningful purchasing power. This vertical integration allows CVS to negotiate terms and absorb fixed operating costs better than standalone peers. Scale alone does not guarantee excess economic returns. Morningstar's 2026 commentary assigns CVS a No Moat rating, stating that past acquisitions diluted economic profitability. We focus on sustained capital returns rather than sheer corporate size.
Pro insight: Vertical scale in healthcare gives firms bargaining leverage with suppliers, but it rarely produces consumer pricing power. CVS can command favorable terms across its pharmacy networks, yet it often passes savings along to clients while front-store retail volumes remain flat.
Switching costs represent CVS's most reliable structural edge. The company serves roughly 87–88 million PBM members and about 37 million medical plan members in 2026. Corporate benefit managers rarely switch administrators casually because reconfiguring formularies, claims software, and provider networks disrupts employee coverage. Client retention data shows these relationships remain sticky over time.
A few large players handle the vast majority of PBM volume across the country. This concentration makes it difficult for new competitors to build national scale profitably. At the same time, expanding federal regulations and digital price-transparency tools continue to soften this entry barrier.
CVS benefits from familiar branding and neighborhood convenience. Patients want reliability when filling critical prescriptions. These advantages stem from physical convenience and operating scale rather than brand loyalty, since clients select healthcare plans based on coverage networks and price.
CVS shares data and coordinates care across business units, but this coordination functions as operational leverage rather than an expanding network effect. Adding more plan participants does not make the service noticeably more valuable to existing members. We consider this the company's weakest competitive pillar.
Switching costs and cost advantages show up clearly in some business lines, but other units show little pricing power.
Aetna's improved medical benefit ratio demonstrates stricter underwriting discipline and better performance in government insurance programs. The pharmacy services and primary care units also generated healthy top-line expansion in Q2 2026. Health Care Services revenue grew 11.5% year over year, while Health Care Delivery revenue through Oak Street rose nearly 23%. Same-store prescription volume rose 7%, according to Yahoo Finance's 2026 analysis.
Retail pharmacy operations present a distinct contrast. That same report showed front-store retail merchandise sales grew only 1%, illustrating that convenience store traffic generates little economic moat. An S&P Global Ratings update noted adjusted debt to EBITDA of 3.8x, projecting modest EBITDA margin gains to 5.3% through 2027. CVS trades at a visible discount to peers, reflecting investor questions about overall profitability.
In our view, the moat shows up in underwriting efficiency, care delivery expansion, and pharmacy volumes. It has not yet translated into premium margins across the entire enterprise.
We rate the moat trend as stable. The positive and negative forces acting on the company's competitive position currently offset each other.
Several positive factors support our rating. Caremark ended 2025 with strong client retention, according to CVS's 2025 annual results. Aetna's underwriting recovery adds additional stability. CVS is also rolling out smaller neighborhood pharmacy locations in 2026 to focus on prescription access and lower overhead costs.
Other dynamics threaten the moat. Changes to Medicare Advantage quality star ratings create financial risk for Aetna by limiting future quality bonus payouts. Aetna's exit from individual health insurance exchanges reduced enrollment by around 700,000. Scrutiny from state and federal regulators over PBM business practices also remains high.
We monitor several indicators to evaluate the long-term trend:
Investors can monitor operational signals as earnings reports come out. A StockIntent watchlist helps investors track revenue, margins, free cash flow, and other relevant ratios in one place.
We assign CVS a medium uncertainty rating based on the range of potential business outcomes over the coming years.
Core revenue streams remain predictable. Management expects at least $414 billion in 2026 revenue. Second-quarter revenue exceeded $106 billion, up more than 7% from the previous year, according to earnings call transcripts. Healthcare utilization and essential prescription refills hold steady during broader economic slowdowns.
Other variables widen the range of outcomes. Spikes in medical utilization, shifting policy for pharmacy benefit managers, and Medicare rating downgrades can compress operating margins quickly. While second-quarter adjusted operating income rose 35% year over year to $5.2 billion, management maintained a cautious outlook for the rest of 2026 due to volatile claims costs. These swing factors justify a medium rating rather than a low one.
Our assessment remains unchanged: CVS possesses a narrow moat, a stable trend, and medium uncertainty. The primary question is whether the company can turn its integration into sustained returns above its cost of capital. Improving underwriting margins and Caremark client retention support our rating, while regulatory inquiries and retail headwinds keep our optimism measured.
Investors should keep an eye on medical-cost inflation, pharmacy benefit regulations, and Medicare Advantage performance scores. Tracking these metrics through quarterly filings will show whether CVS's long-term competitive position is expanding or contracting.
This analysis is for informational and educational purposes only and does not constitute investment advice.
Start your 7-day free trial and find quality compounders faster.
— StockIntent Score ╌ S&P 500
